SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

Home・Akciju saraksts・Bayer AG

Bayer AG

Atvērts

SektorsFinanšu

38.61 0.44

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

38.39

Max

38.78

Galvenie mērījumi
By Trading Economics
Ienākumi	6.5B 2.8B
Pārdošana	2B 13B
EPS	2.812
Dividenžu ienesīgums	0.29
Peļņas marža	20.612
Darbinieki	87,757
EBITDA	2.3B 4.4B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+25.11% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	0.29% 4.64%
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	737M 37B
Iepriekšējā atvēršanas cena	38.17
Iepriekšējā slēgšanas cena	38.61

Ziņu noskaņojums

By Acuity

34%

66%

91 / 438 Rangs Finance

Bayer AG Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. maijs 11:24 UTC

Peļņas

Galvenie tirgus virzītāji

Bayer Shares Climb After Earnings Beat Expectations

2026. g. 12. maijs 06:10 UTC

Peļņas

Bayer Net Profit Surges Driven by Growth in Agricultural Division

2026. g. 6. maijs 10:51 UTC

Iegādes, apvienošanās, pārņemšana

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion -- Update

2026. g. 6. maijs 07:01 UTC

Iegādes, apvienošanās, pārņemšana

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

2026. g. 12. maijs 12:05 UTC

Karstas akcijas

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

2026. g. 12. maijs 10:51 UTC

Karstas akcijas

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

2026. g. 12. maijs 09:08 UTC

Karstas akcijas

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

2026. g. 12. maijs 05:38 UTC

Peļņas

Bayer Backs 2026 Outlook Adjusted for Currency

2026. g. 12. maijs 05:36 UTC

Peļņas

Bayer 1Q Consumer Health Sales Grew 5.3%, Adjusted for Currency, Portfolio Changes

2026. g. 12. maijs 05:36 UTC

Peļņas

Bayer 1Q Pharma Sales Fell 0.5%, Adjusted for Currency, Portfolio Changes

2026. g. 12. maijs 05:36 UTC

Peļņas

Bayer 1Q Crop Science Sales Grew 6.8%, Adjusted for Currency, Portfolio Changes

2026. g. 12. maijs 05:35 UTC

Peļņas

Bayer 1Q Adj EPS EUR2.71

2026. g. 12. maijs 05:34 UTC

Peļņas

Analysts Saw Bayer 1Q Net Profit From Continuing Operations at EUR1.60B

2026. g. 12. maijs 05:34 UTC

Peļņas

Analysts Saw Bayer 1Q Ebitda Before Special Items at EUR3.93B

2026. g. 12. maijs 05:34 UTC

Peļņas

Analysts Saw Bayer 1Q Sales at EUR13.42B

2026. g. 12. maijs 05:34 UTC

Peļņas

Bayer 1Q Sales Grew 4.1% When Adjusted for Currency, Portfolio Changes

2026. g. 12. maijs 05:33 UTC

Peļņas

Bayer 1Q EBIT EUR3.53B

2026. g. 12. maijs 05:32 UTC

Peļņas

Bayer 1Q Ebitda Before Special Items EUR4.45B

2026. g. 12. maijs 05:32 UTC

Peļņas

Bayer 1Q Net Pft EUR2.76B

2026. g. 12. maijs 05:31 UTC

Peļņas

Bayer 1Q Sales EUR13.405B

2026. g. 12. maijs 05:31 UTC

Peļņas

Bayer Backs 2026 View

2026. g. 6. maijs 06:34 UTC

Iegādes, apvienošanās, pārņemšana

Bayer: Perfuse's Lead Program Is Treatment for Glaucoma and Diabetic Retinopathy

2026. g. 6. maijs 06:33 UTC

Iegādes, apvienošanās, pārņemšana

Bayer: Acquisition Aims to Complement Ophthalmology Pipeline

2026. g. 6. maijs 06:33 UTC

Iegādes, apvienošanās, pārņemšana

Bayer: Additional Payments Subject to Development, Regulatory, and Commercial Milestones

2026. g. 6. maijs 06:32 UTC

Iegādes, apvienošanās, pārņemšana

Bayer to Pay $300M Upfront

2026. g. 6. maijs 06:32 UTC

Iegādes, apvienošanās, pārņemšana

Bayer to Buy Perfuse Therapeutics for Up to $2.45B

2026. g. 6. maijs 06:31 UTC

Iegādes, apvienošanās, pārņemšana

Bayer to Buy Perfuse Therapeutics

2026. g. 6. maijs 06:30 UTC

Iegādes, apvienošanās, pārņemšana

Bayer To Acquire Perfuse Therapeutics To Complement Ophthalmology Pipeline >BAYN.XE

2026. g. 8. apr. 14:41 UTC

Peļņas

Buy Johnson & Johnson Stock Ahead of Earnings, Analyst Says. The Gains Can Continue. -- Barrons.com

2026. g. 1. apr. 14:24 UTC

Tirgus saruna

Bayer Pharma Head Touts Healthiest Pipeline in Company's History -- Market Talk

Salīdzinājums

Cenas izmaiņa

Bayer AG Prognoze

Cenas mērķis

By TipRanks

25.11% augšup

Prognoze 12 mēnešiem

Vidējais 48.18 EUR 25.11%

Augstākais 56 EUR

Zemākais 25 EUR

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Bayer AG — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Bayer AG — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

91 / 438 Rangs Finanšu

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.